Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2019 · 10-Q
Revenue—
Net Income-$10.01M-$10.01MN/M vs Q2 2018 EPS Diluted-$0.37-$0.37N/M vs Q2 2018 Operating Income-$10,512,000N/M Operating Cash Flowderived-$8,747,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,012,000N/M ended Jun 30, 2019 · filed Aug 6, 2019 · 37 d after period end